Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring

BACKGROUND: Dasatinib is a potent, multi-targeted kinase inhibitor that was recently approved for treatment of chronic myelogenous leukemia resistant to imatinib. To aid the clinical development of dasatinib in prostate cancer, we utilized preclinical models to identify potential molecular markers f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xi-De, Reeves, Karen, Luo, Feng R, Xu, Li-An, Lee, Francis, Clark, Edwin, Huang, Fei
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258199/
https://www.ncbi.nlm.nih.gov/pubmed/18047674
http://dx.doi.org/10.1186/gb-2007-8-11-r255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258199/
https://www.ncbi.nlm.nih.gov/pubmed/18047674
http://dx.doi.org/10.1186/gb-2007-8-11-r255

Ejemplares similares